Please use this identifier to cite or link to this item:
Title: A phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases.
Austin Authors: Zalcberg, John R;Pietersz, Geoffrey A;Toohey, B;Laird, J;Huggins, R;Zimet, A S;Hennessy, O F;McKenzie, A;McKenzie, Ian F C
Affiliation: Medical Oncology Department, Heidelberg Repatriation Hospital, Victoria, Australia
Issue Date: 16-May-1994
Publication information: European Journal of Cancer (oxford, England : 1990); 30A(9): 1227-31
Abstract: A phase I/II study of the intralesional administration of ricin-labelled monoclonal antibodies was conducted in patients with hepatic metastases of gastrointestinal origin. The anti-carcinoembryonic antigen (CEA) antibody I-1 was conjugated to blocked ricin via a disulphide bridge. After a test dose of antibody, patients were injected with ricin-antibody conjugates under computed tomography (CT) guidance on two occasions 1 week apart. Patients with stable or responding disease would receive a third course. The dose of ricin relative to surface area was increased in a predefined manner in cohorts of 3 patients. A total of 27 patients with hepatic metastases were entered into this study. All patients had metastatic colorectal cancer (26 patients) or adenocarcinoma of unknown primary with elevated CEA levels (1 patient). The presence of malignancy was documented cytologically in 9 of 11 patients tested. Minor responses were seen in 7 patients. However, no major objective responses or changes in the growth rate of injected lesions were observed. Toxicity was generally mild, the most common being hepatic capsular pain 24-48 h after each injection. 6 patients experienced rigors. One patient had anaphylaxis. Human anti-mouse and anti-ricin antibody responses were observed. Although substantial amounts of ricin conjugated to monoclonal antibodies were delivered into single lesions, this therapeutic approach was unsuccessful. Future studies of ricin-labelled antibodies should incorporate the systemic administration of immunoconjugates.
Gov't Doc #: 7999404
Journal: European journal of cancer (Oxford, England : 1990)
Type: Journal Article
Subjects: Adenocarcinoma.secondary.therapy
Antibodies, Monoclonal.administration & dosage
Carcinoembryonic Antigen.metabolism
Gastrointestinal Neoplasms.metabolism.therapy
Immunotoxins.administration & dosage
Injections, Intralesional
Liver Neoplasms.metabolism.radiography.secondary.therapy
Middle Aged
Ricin.administration & dosage
Tomography, X-Ray Computed
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.